Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
A Swiss product called Redensyl, which is supposed to target hair follicle stemcells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stemcells, but minoxidil and finasteride are still the main treatments.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stemcells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.